SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026)
SAB Biotherapeutics (SABS) reported Depreciation & Amortization (CF) of $730965.0 for Q1 2026, down 8.63% on a YoY basis from $800000.0 in Q1 2025, and up 5.21% quarter-over-quarter from $694763.0 in Q4 2025.
SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $730965.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 8.63% year-over-year to $730965.0; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 16.55% YoY), and the FY2025 full-year result was $3.0 million, down 36.36% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $730965.0, up from $694763.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.0 million in Q1 2024, with the low at $636235.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $906207.5 across 5 years, with a median of $890000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 189.7% — and 2025, when it sank 60.0%.
- SAB Biotherapeutics' Depreciation & Amortization (CF) stood at $930000.0 in 2022, then rose by 4.23% to $969340.0 in 2023, then decreased by 16.87% to $805771.0 in 2024, then retreated by 13.78% to $694763.0 in 2025, then grew by 5.21% to $730965.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $730965.0 (Q1 2026), $694763.0 (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 730,965.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 730,965.00 |
| Mar 31, 2026 | 730,965.00 |
| Dec 31, 2025 | 694,763.00 |
| Dec 31, 2025 | 694,763.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 805,771.00 |
| Dec 31, 2024 | 805,771.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 969,340.00 |
| Dec 31, 2023 | 969,340.00 |